Qualigen to participate in next funding round for NanoSynex
Qualigen Therapeutics (NASDAQ: QLGN) has announced its participation as the lead investor in NanoSynex's 2025 bridge funding round, which aims to raise up to $500,000. NanoSynex is developing advanced Antimicrobial Susceptibility Testing (AST) technology that promises to cut testing time in half while providing more robust diagnostics.
The technology aims to optimize antibiotic usage globally through improved testing methods. NanoSynex's Minimum Viable Product (MVP) System offers competitive advantages over existing solutions, both in performance and pricing. The company is targeting EU market approval in 2027 and US approval in 2028.
The global AST market is projected to reach $4.7 billion by 2027, with the US market expected to account for $1.6 billion. NanoSynex has secured four patents for their technology and maintains a strong pipeline for additional applications and verticals.
Qualigen Therapeutics (NASDAQ: QLGN) ha annunciato la sua partecipazione come investitore principale nel round di finanziamento di ponte di NanoSynex nel 2025, che mira a raccogliere fino a 500.000 dollari. NanoSynex sta sviluppando una tecnologia avanzata di Test di Sensibilità Antimicrobica (AST) che promette di dimezzare i tempi di test mantenendo diagnosi più robuste.
La tecnologia si propone di ottimizzare l'uso degli antibiotici a livello globale attraverso metodi di test migliorati. Il Minimum Viable Product (MVP) System di NanoSynex offre vantaggi competitivi rispetto alle soluzioni esistenti, sia in termini di prestazioni che di costo. L'azienda punta ad ottenere l'approvazione del mercato UE nel 2027 e l'approvazione negli Stati Uniti nel 2028.
Il mercato globale degli AST è previsto raggiungere 4,7 miliardi di dollari entro il 2027, con il mercato statunitense che dovrebbe rappresentare 1,6 miliardi di dollari. NanoSynex ha ottenuto quattro brevetti per la propria tecnologia e mantiene un forte portafoglio per ulteriori applicazioni e settori.
Qualigen Therapeutics (NASDAQ: QLGN) ha anunciado su participación como inversor principal en la ronda de financiamiento puente de NanoSynex en 2025, que tiene como objetivo recaudar hasta 500,000 dólares. NanoSynex está desarrollando una tecnología avanzada de Pruebas de Susceptibilidad Antimicrobiana (AST) que promete disminuir el tiempo de prueba a la mitad, al tiempo que proporciona diagnósticos más sólidos.
La tecnología busca optimizar el uso de antibióticos a nivel mundial mediante métodos de prueba mejorados. El sistema de Producto Mínimo Viable (MVP) de NanoSynex ofrece ventajas competitivas sobre las soluciones existentes, tanto en rendimiento como en precios. La empresa está buscando la aprobación del mercado de la UE en 2027 y la aprobación en EE. UU. en 2028.
Se prevé que el mercado global de AST alcance 4.7 mil millones de dólares para 2027, con el mercado estadounidense que se espera represente 1.6 mil millones de dólares. NanoSynex ha asegurado cuatro patentes para su tecnología y mantiene un sólido pipeline para aplicaciones y verticales adicionales.
Qualigen Therapeutics (NASDAQ: QLGN)는 2025년 NanoSynex의 브릿지 자금 조달 라운드에 주요 투자자로 참여한다고 발표했습니다. 이 라운드는 최대 50만 달러를 모금하는 것을 목표로 하고 있습니다. NanoSynex는 테스트 시간을 절반으로 줄이고 더 강력한 진단을 제공할 수 있는 첨단 항균성 시험(AST) 기술을 개발하고 있습니다.
이 기술은 개선된 테스트 방법을 통해 전 세계적으로 항생제 사용을 최적화하는 것을 목표로 하고 있습니다. NanoSynex의 최소 실행 가능 제품(MVP) 시스템은 성능과 가격 면에서 기존 솔루션에 비해 경쟁 우위를 제공합니다. 이 회사는 2027년 EU 시장 승인과 2028년 미국 승인을 목표로 하고 있습니다.
글로벌 AST 시장은 2027년까지 47억 달러에 이를 것으로 예상되며, 미국 시장은 16억 달러를 차지할 것으로 보입니다. NanoSynex는 기술에 대해 네 개의 특허를 확보했으며 추가 애플리케이션과 수직 시장을 위한 강력한 파이프라인을 유지하고 있습니다.
Qualigen Therapeutics (NASDAQ: QLGN) a annoncé sa participation en tant qu'investisseur principal dans le tour de financement relais de NanoSynex en 2025, qui vise à lever jusqu'à 500 000 dollars. NanoSynex développe une technologie avancée de Tests de Sensibilité Antimicrobienne (AST) qui promet de réduire le temps de test de moitié tout en fournissant des diagnostics plus robustes.
La technologie vise à optimiser l'utilisation des antibiotiques dans le monde entier grâce à des méthodes de test améliorées. Le Minimum Viable Product (MVP) System de NanoSynex offre des avantages concurrentiels par rapport aux solutions existantes, tant en termes de performance que de prix. L'entreprise vise une approbation sur le marché de l'UE d'ici 2027 et une approbation aux États-Unis d'ici 2028.
Le marché mondial des AST devrait atteindre 4,7 milliards de dollars d'ici 2027, le marché américain devant représenter 1,6 milliard de dollars. NanoSynex a sécurisé quatre brevets pour sa technologie et maintient un solide pipeline pour des applications et des secteurs supplémentaires.
Qualigen Therapeutics (NASDAQ: QLGN) hat seine Teilnahme als Hauptinvestor in der Brückenfinanzierungsrunde von NanoSynex im Jahr 2025 angekündigt, die darauf abzielt, bis zu 500.000 Dollar zu sammeln. NanoSynex entwickelt eine fortschrittliche Antimikrobielle Empfindlichkeitstest (AST)-Technologie, die verspricht, die Testzeiten zu halbieren und gleichzeitig robustere Diagnosen zu liefern.
Die Technologie zielt darauf ab, den Antibiotikaeinsatz weltweit durch verbesserte Testmethoden zu optimieren. Das Minimale Lebensfähige Produkt (MVP) System von NanoSynex bietet wettbewerbliche Vorteile gegenüber bestehenden Lösungen, sowohl in Bezug auf Leistung als auch auf Preis. Das Unternehmen strebt an, 2027 die Marktzulassung in der EU und 2028 die Zulassung in den USA zu erhalten.
Der globale AST-Markt wird voraussichtlich bis 2027 4,7 Milliarden Dollar erreichen, wobei der US-Markt voraussichtlich 1,6 Milliarden Dollar ausmachen wird. NanoSynex hat vier Patente für seine Technologie gesichert und verfügt über eine starke Pipeline für weitere Anwendungen und Sektoren.
- None.
- None.
Market size expected to reach
CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to
“We are very excited to participate and be the first investors to commit in this round of funding for NanoSynex. The technology they are developing will help the world of Antimicrobial Susceptibility Testing (AST) by reducing the time required for tests in half, offering more robust diagnostics, which will lead to better use and not over use of the wrong antibiotics for patients globally. The Minimum Viable Product (MVP) System has numerous competitive advantages to existing tests and is priced competitively with those slower and less robust products.”, stated Kevin Richardson II, CEO of Qualigen. NanoSynex plans to be approved for the EU market in 2027 and US in 2028. The market size globally is expected to reach
Diane Abensur, CEO of NanoSynex, stated, “We are thrilled to have Qualigen’s involvement in being the first to commit to this bridge round funding. It will allow us to jump start our product development of our MVP system for AST, generation 2.0 . The need for our product and the lives we can help save by getting more timely and accurate robust diagnostics will help NanoSynex grow dramatically.”
ABOUT NANOSYNEX
NanoSynex is a MedTech company, based in Israel, that aims at providing new solutions to improve testing quality and reduce healthcare costs by speeding up diagnostic processes.
Today, NanoSynex is focused on the development and commercialization of a rapid innovative Antimicrobial Susceptibility Test (AST). The technology is based on a purely phenotypic approach and uses a microfluidic disposable test card platform and method that optimizes bacterial growth. This disruptive development was born from exciting research discoveries at the lab of Professor Shulamit Levenberg, former Dean of the Technion Institute of Technology – Biomedical Engineering Faculty.
NanoSynex’s team is composed of passionate, dedicated business executives, top-notch biomedical engineers and microbiologist team members and supported by a network of experts, including strategic alliances with future distributors, that know how to bring this revolutionary product to the market.
About Qualigen Therapeutics, Inc.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq’s continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
ir@qlgntx.com.
FAQ
What is the expected market size for NanoSynex's AST technology by 2027?
When does NanoSynex plan to receive regulatory approvals for their AST technology?
How much funding is NanoSynex seeking to raise in their 2025 bridge round?
What are the key advantages of NanoSynex's MVP System for AST testing?
How many patents does NanoSynex currently hold for their AST technology?
